Feist-Weiller's Lori Panu and Dr. Gary Burton will be heading their site as part a massive study involving an aspirin regimen in the elderly.
Feist-Weiller Cancer Center in Shreveport is recruiting patients for a study underway in the United States and Australia that will follow 19,000 people who are 65 and older to look at the risk and benefits of an aspirin-a-day regimen. The placebo-controlled clinical trial will look at whether there are potential benefits for the prevention of heart disease, certain cancers and even dementia. But are the known risks of gastrointestinal bleeding and stroke too great? Dr. Gary Burton, clinical research director at Feist-Weiller, said it’s time to find out.